NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US
18. Juni 2024 07:00 ET
|
NMD Pharma
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US Aarhus, Denmark, 18 June 2024 – NMD Pharma A/S, a clinical-stage...
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US
18. Juni 2024 01:00 ET
|
NMD Pharma
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US Aarhus, Denmark, 18 June 2024 – NMD Pharma A/S, a clinical-stage...
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors
03. Januar 2023 07:00 ET
|
NMD Pharma
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors Brings 30 years of experience building private and public development-stage and commercial biopharmaceutical companies and has...
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors
03. Januar 2023 01:00 ET
|
NMD Pharma
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors Brings 30 years of experience building private and public development-stage and commercial biopharmaceutical companies and has...
NMD Pharma expands its US presence
03. Mai 2022 07:00 ET
|
NMD Pharma
PRESS RELEASE NMD Pharma expands its US presence Creates US subsidiary and increases US R&D and staff recruitment activity Aarhus, Denmark, 3 May 2022 – NMD Pharma A/S, a clinical stage biotech...
NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670
30. Juni 2021 07:00 ET
|
NMD Pharma
NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670 Aarhus, Denmark, 30 June 2021 – NMD Pharma A/S, a biotech company leading in the development...
NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670
30. Juni 2021 02:00 ET
|
NMD Pharma
NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670 Aarhus, Denmark, 30 June 2021 – NMD Pharma A/S, a biotech company leading in the development...
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
14. Juli 2020 07:00 ET
|
NMD Pharma
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 14 July 2020 – NMD Pharma A/S, a biotech...
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
14. Juli 2020 02:00 ET
|
NMD Pharma
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 14 July 2020 – NMD Pharma A/S, a biotech...